Fig. 1 · Structure

Documents & Downloads

Carboplatin

Cat. No. A10182 CAS 41575-94-4

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). Cisplatin and carboplatin, as well as oxaliplatin, interact with DNA, akin to the mechanism of alkylating agents.

In Stock

Publications for Carboplatin

4 publications citing this product

  1. Seungyeon Ryu, .et al. , Breast Cancer Res, 2025, Jun 23;27(1):113 PMID: 40551232
  2. Hye Ryeong Jun, .et al. , Biomaterials, 2023, May;296:122087 PMID: 36924663
  3. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  4. Jianwei Dou, .et al. , J Sep Sci, 2020, Dec 4 PMID: 33275824

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
DNA synthesis (A2780, SKOV-3, IGROV-1, HX62 cells)

Carboplatin Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Carboplatin from 1 published reference.

Carboplatin In Vitro Studies

Carboplatin reduced viable-cell readouts in ovarian cancer spheroids with model-dependent potency. After 24 h exposure and 24 h recovery, the reported IC50 values were 75.32 µM for OV1946 and 280.8 µM for TOV21G. These assay-specific estimates do not establish a universal cellular potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Carboplatin response in ovarian cancer spheroids

Cell-based study · OV1946 and TOV21G ovarian cancer cell-line spheroids; representative models from a six-line panel. [1]

Viability responses differed by model. The fitted IC50 was 75.32 µM in OV1946 and 280.8 µM in TOV21G. These are endpoint estimates after exposure and recovery, rather than fixed treatment doses. The disputed OV4453 spheroid IC50 is excluded.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viable-cell proportion after carboplatin exposure and recoveryIC50 75.32 µM[1]
Viable-cell proportion after carboplatin exposure and recoveryIC50 280.8 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
OV1946: 12, 60 and 300 µM; TOV21G: 60, 180 and 540 µM (final in-well concentrations).
Exposure duration
24 h treatment followed by 24 h recovery.
Method
Carboplatin added to preformed spheroids; complete OSE medium added to untreated controls. Ten spheroids pooled per replicate; two replicates per condition.
Co-treatment
Carboplatin alone.
Reported limits
No additional drug solvent is specified for spheroid treatment in the retrieved methods. IC50 uncertainty intervals are not supplied in Figure 3.
Methods and source locations

Compound reported in the paper: Carboplatin; Compound label in the paper: Carboplatin

Reported experimental carboplatin responses; no supplier-lot validation or clinical dose extrapolation.

Figure 3C–D; Methods, 3D spheroid formation, Carboplatin treatment/3D spheroid model, Flow cytometry analysis, Statistical analyses

Viable-cell proportion after carboplatin exposure and recovery: LIVE-DEAD Fixable Aqua staining and flow cytometry; normalized dose–response regression. Three independent experiments, two replicates per condition; curves show mean ± SEM. — Figure 3C–D; Results, Carboplatin response of 3D EOC spheroids; Methods, Flow cytometry analysis of 3D spheroids

Viable-cell proportion after carboplatin exposure and recovery: Same experiment and assay design as OV1946. Three independent experiments, two replicates per condition; curves show mean ± SEM. — Figure 3C–D; Methods, Flow cytometry analysis of 3D spheroids

Carboplatin In Vivo Studies

Carboplatin produced heterogeneous responses across ovarian cancer xenografts. Weekly intraperitoneal treatment at 25–75 mg/kg suppressed tumor growth in responsive models, whereas TOV21G and TOV112D showed no significant tumor-volume response even at 75 mg/kg. Activity therefore depended on the tumor model and tested dose. [1]

Model-dependent carboplatin response in ovarian cancer xenografts

Animal study · OV1946, OV4453, OV4485, OV90, TOV21G and TOV112D subcutaneous xenografts in female NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ immunodeficient mice. [1]

At sacrifice, OV1946 and OV4453 tumors were significantly smaller than controls at all three tested doses. OV4485 and OV90 responded at 50 and 75 mg/kg but not at 25 mg/kg. TOV21G and TOV112D showed no significant tumor-volume difference even at 75 mg/kg. Ki-67 responses were not identical to volume responses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume relative to saline controls at sacrificeTumor-volume response OV1946 and OV4453: significant at 25, 50 and 75 mg/kg; OV4485 and OV90: significant at 50 and 75 mg/kg only; TOV21G and TOV112D: no significant difference at tested doses.[1]
Ki-67 staining normalized to controlQualitative statistical pattern OV90: significant reduction only at 75 mg/kg; TOV21G and TOV112D: no significant reduction at tested doses.[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once weekly
Treatment course
Up to six cycles; ethical limits could shorten treatment.
Vehicle
0.9% NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Carboplatin 25 mg/kg0.9% NaCl vehicle; N = 8 per condition per cell line.OV1946 and OV4453 tumor volumes significantly lower than control; OV4485, OV90, TOV21G and TOV112D showed no significant tumor-volume difference.[1]
Carboplatin 50 mg/kg0.9% NaCl vehicle; N = 8 per condition per cell line.OV1946, OV4453, OV4485 and OV90 tumor volumes significantly lower than control; TOV21G and TOV112D showed no significant tumor-volume difference.[1]
Carboplatin 75 mg/kg0.9% NaCl vehicle; N = 8 per condition per cell line.OV1946, OV4453, OV4485 and OV90 tumor volumes significantly lower than control; TOV21G and TOV112D showed no significant tumor-volume difference.[1]
Carboplatin 25 mg/kg
Model: OV1946, OV4453, OV4485, OV90, TOV21G and TOV112D subcutaneous xenografts in female NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ immunodeficient mice.
Reported limits: Individual cumulative dose and per-animal cycle counts are not provided in the selected evidence.
Carboplatin 50 mg/kg
Model: OV1946, OV4453, OV4485, OV90, TOV21G and TOV112D subcutaneous xenografts in female NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ immunodeficient mice.
Reported limits: Individual cumulative dose and per-animal cycle counts are not provided in the selected evidence.
Carboplatin 75 mg/kg
Model: OV1946, OV4453, OV4485, OV90, TOV21G and TOV112D subcutaneous xenografts in female NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ immunodeficient mice.
Reported limits: Individual cumulative dose and per-animal cycle counts are not provided in the selected evidence.
Methods and source locations

Compound reported in the paper: Carboplatin; Compound label in the paper: Carboplatin (Hospira)

Reported experimental carboplatin responses; no supplier-lot validation or clinical dose extrapolation.

Figure 2A–C; Methods, Xenograft mouse model, Carboplatin treatment/Xenograft mouse model, IF quantification, Statistical analyses; Results first subsection

Tumor volume relative to saline controls at sacrifice: Caliper measurements 2–3 times weekly; N = 8 tumors per condition per cell line; mean ± SEM; one-way ANOVA. No exact volume reduction estimated from plotted curves. — Figure 2B; Results, Carboplatin sensitivity of 2D EOC cell cultures differs from the in vivo response; Methods, Xenograft mouse model and Statistical analyses

Ki-67 staining normalized to control: Immunofluorescence quantification; mean ± SEM; normalized Ki-67-positive area. This secondary endpoint does not establish uniform antiproliferative activity across models. — Figure 2C; Methods, IF quantification/Xenograft experiments

Carboplatin 25 mg/kg · Figure 2A–B; Methods, Xenograft mouse model and Carboplatin treatment/Xenograft mouse model

Carboplatin 50 mg/kg · Figure 2A–B; Methods, Xenograft mouse model and Carboplatin treatment/Xenograft mouse model

Carboplatin 75 mg/kg · Figure 2A–B; Methods, Xenograft mouse model and Carboplatin treatment/Xenograft mouse model

Specifications

Manufacturer Adooq Bioscience
CAS Number 41575-94-4
Formula C6H12N2O4Pt
Molecular Weight 371.3
Synonyms Paraplatin
SMILES
C1CC(C1)(C(=O)O)C(=O)O.N.N.[Pt]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Warmed: 14 mg/mL (37.71 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Carboplatin Research References

  1. [1] Melica Nourmoussavi Brodeur, Kayla Simeone, Kim Leclerc-Deslauniers, et al. Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models Scientific Reports (2021). PMID: 34521878 DOI: 10.1038/s41598-021-97434-w Source material

Publications

4 publications citing this product

  1. Seungyeon Ryu, .et al. , Breast Cancer Res, 2025, Jun 23;27(1):113 PMID: 40551232
  2. Hye Ryeong Jun, .et al. , Biomaterials, 2023, May;296:122087 PMID: 36924663
  3. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  4. Jianwei Dou, .et al. , J Sep Sci, 2020, Dec 4 PMID: 33275824

Added to your cart

View Cart Checkout
Loading...